Recent 8-K filings for RNA

• July 14, 2026, 5:14 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Atrium Therapeutics receives FDA IND clearance for ATR 1072 in PRKAG2 syndrome; Phase 1/2 trial to start

  FDA cleared IND for ATR 1072, a precision cardiology RNA therapeutic for PRKAG2 syndrome.

• May 14, 2026, 4:50 PM ET earnings materiality 0.55 neutral item 2.02item 9.01 ◈ Earnings Releases

  Atrium Therapeutics reports Q1 collaboration revenue $19.6M, driven by $15M BMS milestone; cash $267.8M

  Collaboration revenue $19.6M in Q1 2026, primarily a $15M milestone from BMS partnership.

• February 27, 2026, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 5.01item 5.02item 9.01 ◈ Material Agreements ×2◈ M&A Transactions

  Atrium Therapeutics completes spin-off from Avidity; begins trading under RNA on Nasdaq

  Separation of Atrium Therapeutics (SpinCo) from Avidity effective Feb 26, 2026; one SpinCo share for every ten Avidity shares distributed.

• February 26, 2026, 6:59 PM ET other material materiality 0.75 neutral item 7.01item 9.01

  Atrium Therapeutics completes spin-off from Avidity; 15.5M shares distributed, trading begins Feb 27 under RNA

  Avidity distributed 15,514,966 Atrium shares at a ratio of 1 share per 10 Avidity shares; holds no equity interest after.

Materiality & sentiment trend

Max materiality 0.75 · Median 0.70 · Most common event other_material

1 positive 0 negative 3 neutral

source · RNA on sec.gov